Literature DB >> 18987146

Enhanced induction of intestinal cellular immunity by oral priming with enteric adenovirus 41 vectors.

Sung-Youl Ko1, Cheng Cheng, Wing-Pui Kong, Lingshu Wang, Masaru Kanekiyo, David Einfeld, C Richter King, Jason G D Gall, Gary J Nabel.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) infection is characterized by the rapid onset of intestinal T-cell depletion that initiates the progression to AIDS. The induction of protective immunity in the intestinal mucosa therefore represents a potentially desirable feature of a preventive AIDS vaccine. In this study, we have evaluated the ability of an enteric adenovirus, recombinant adenovirus 41 (rAd41), to elicit intestinal and systemic immune responses by different immunization routes, alone or in combination with rAd5. rAd41 expressing HIV envelope (Env) protein induced cellular immune responses comparable to those of rAd5-based vectors after either a single intramuscular injection or a DNA prime/rAd boost. Oral priming with rAd41-Env followed by intramuscular boosting with rAd5-Env stimulated a more potent CD8(+) T-cell response in the small intestine than the other immunization regimens. Furthermore, the direct injection of rAd41-Env into ileum together with intramuscular rAd5-Env boosting increased Env-specific cellular immunity markedly in mucosal as well as systemic compartments. These data demonstrate that heterologous rAd41 oral or ileal priming with rAd5 intramuscular boosting elicits enhanced intestinal mucosal cellular immunity and that oral or ileal vector delivery for primary immunization facilitates the generation of mucosal immunity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18987146      PMCID: PMC2612352          DOI: 10.1128/JVI.01811-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.

Authors:  Bimal K Chakrabarti; Wing-pui Kong; Bei-yue Wu; Zhi-Yong Yang; Jacques Friborg; Xu Ling; Steven R King; David C Montefiori; Gary J Nabel
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

Review 2.  Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know.

Authors:  Giuseppe Pantaleo; Richard A Koup
Journal:  Nat Med       Date:  2004-08       Impact factor: 53.440

3.  Mediastinal lymph node CD8alpha- DC initiate antigen presentation following intranasal coadministration of alpha-GalCer.

Authors:  Sung-Youl Ko; Kyoo-A Lee; Hyun-Jun Youn; Yeon-Jeong Kim; Hyun-Jeong Ko; Tae-Hwe Heo; Mi-Na Kweon; Chang-Yuil Kang
Journal:  Eur J Immunol       Date:  2007-08       Impact factor: 5.532

4.  Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system.

Authors:  Franck Lemiale; Wing-pui Kong; Levent M Akyürek; Xu Ling; Yue Huang; Bimal K Chakrabarti; Michael Eckhaus; Gary J Nabel
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

5.  Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques.

Authors:  I M Belyakov; Z Hel; B Kelsall; V A Kuznetsov; J D Ahlers; J Nacsa; D I Watkins; T M Allen; A Sette; J Altman; R Woodward; P D Markham; J D Clements; G Franchini; W Strober; J A Berzofsky
Journal:  Nat Med       Date:  2001-12       Impact factor: 53.440

6.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

7.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection.

Authors:  Douglas D Richman; Terri Wrin; Susan J Little; Christos J Petropoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

8.  Cutting edge: conventional CD8 alpha+ dendritic cells are generally involved in priming CTL immunity to viruses.

Authors:  Gabrielle T Belz; Christopher M Smith; Daniel Eichner; Ken Shortman; Guna Karupiah; Francis R Carbone; William R Heath
Journal:  J Immunol       Date:  2004-02-15       Impact factor: 5.422

9.  Subgroup B and F fiber chimeras eliminate normal adenovirus type 5 vector transduction in vitro and in vivo.

Authors:  John W Schoggins; Jason G D Gall; Erik Falck-Pedersen
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

10.  Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract.

Authors:  Saurabh Mehandru; Michael A Poles; Klara Tenner-Racz; Amir Horowitz; Arlene Hurley; Christine Hogan; Daniel Boden; Paul Racz; Martin Markowitz
Journal:  J Exp Med       Date:  2004-09-13       Impact factor: 14.307

View more
  15 in total

1.  Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.

Authors:  Jeffrey D Lifson; Nancy L Haigwood
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

2.  Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytes.

Authors:  David R Kaufman; Maytal Bivas-Benita; Nathaniel L Simmons; Darby Miller; Dan H Barouch
Journal:  J Virol       Date:  2010-03-31       Impact factor: 5.103

3.  Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates.

Authors:  Lukas Flatz; Cheng Cheng; Lingshu Wang; Kathryn E Foulds; Sung-Youl Ko; Wing-Pui Kong; Rahul Roychoudhuri; Wei Shi; Saran Bao; John-Paul Todd; Mohammed Asmal; Ling Shen; Mitzi Donaldson; Stephen D Schmidt; Jason G D Gall; Daniel D Pinschewer; Norman L Letvin; Srinivas Rao; John R Mascola; Mario Roederer; Gary J Nabel
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

Review 4.  Viruses as vaccine vectors for infectious diseases and cancer.

Authors:  Simon J Draper; Jonathan L Heeney
Journal:  Nat Rev Microbiol       Date:  2010-01       Impact factor: 60.633

Review 5.  Immunology of gut mucosal vaccines.

Authors:  Marcela F Pasetti; Jakub K Simon; Marcelo B Sztein; Myron M Levine
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

6.  Induction of mucosal HIV-specific B and T cell responses after oral immunization with live coxsackievirus B4 recombinants.

Authors:  Rui Gu; Cristy Stagnar; Lesya Zaichenko; Arlene I Ramsingh
Journal:  Vaccine       Date:  2012-03-29       Impact factor: 3.641

Review 7.  Translational Mini-Review Series on Vaccines for HIV: T lymphocyte trafficking and vaccine-elicited mucosal immunity.

Authors:  D R Kaufman; D H Barouch
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

8.  Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunity.

Authors:  Lingshu Wang; Cheng Cheng; Sung-Youl Ko; Wing-Pui Kong; Masaru Kanekiyo; David Einfeld; Richard M Schwartz; C Richter King; Jason G D Gall; Gary J Nabel
Journal:  J Virol       Date:  2009-05-06       Impact factor: 5.103

9.  Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study.

Authors:  Marc Gurwith; Michael Lock; Eve M Taylor; Glenn Ishioka; Jeff Alexander; Tim Mayall; John E Ervin; Richard N Greenberg; Cynthia Strout; John J Treanor; Richard Webby; Peter F Wright
Journal:  Lancet Infect Dis       Date:  2013-01-29       Impact factor: 25.071

10.  Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus.

Authors:  Xiaojuan Guo; Yao Deng; Hong Chen; Jiaming Lan; Wen Wang; Xiaohui Zou; Tao Hung; Zhuozhuang Lu; Wenjie Tan
Journal:  Immunology       Date:  2015-04-21       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.